Context Therapeutics (CNTX) Interest & Investment Income (2024 - 2026)
Context Therapeutics (CNTX) posted Interest & Investment Income of $520139.0 for Q1 2026, down 23.79% sequentially from $682484.0 in Q4 2025, and down 45.74% YoY from $958517.0 in Q1 2025.
Context Therapeutics (CNTX) Interest & Investment Income (2024 - 2026) Analysis & Trends
Context Therapeutics has reported Interest & Investment Income for 3 years, with the latest figure at $520139.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 45.74% year-over-year to $520139.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (down 26.61% YoY) and the FY2025 annual result came in at $3.4 million, up 5.57% from the prior year.
- Interest & Investment Income eased to $520139.0 in Q1 2026 per CNTX's latest filing, from $682484.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $1.2 million in Q3 2024 and troughed at $152351.0 in Q1 2024.
- A 3-year average of $788767.6 and a median of $840150.0 in 2024 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2025 and 2026: Interest & Investment Income surged 529.15% in 2025, then sank 45.74% in 2026.
- Over 3 years, Interest & Investment Income stood at $964036.0 in 2024, then declined by 29.21% to $682484.0 in 2025, then declined by 23.79% to $520139.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $520139.0, $682484.0, and $833772.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Context Therapeutics | 48.18 Mn | 48.18 Mn | - | 418,663.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 418,663.00 |
| Mar 31, 2026 | 520,139.00 |
| Dec 31, 2025 | 682,484.00 |
| Sep 30, 2025 | 833,772.00 |
| Jun 30, 2025 | 903,772.00 |
| Mar 31, 2025 | 958,517.00 |
| Dec 31, 2024 | 964,036.00 |
| Sep 30, 2024 | 1.24 Mn |
| Jun 30, 2024 | 840,150.00 |
| Mar 31, 2024 | 152,351.00 |